Ablevia's proprietary platform technology enables selective targeting of harmful antibodies by infusible therapeutics.
We address autoantibodies in autoimmune conditions, neutralizing anti-drug antibodies against biologics and neutralizing anti-viral vector antibodies.
Our antibody depleting compounds are readily adapted to target disease-causing and unwanted antibodies in rare diseases and conditions with unmet clinical needs.
Founded in 2018 at the Vienna Biocenter Campus, Ablevia focuses on preclinical research and development. We are reaching out for programs with strong partners in need of addressing undesired antibodies in preclinical and clinical development.